Stock VICP VICAPSYS LIFE SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Vicapsys Life Sciences, Inc.

Equities

VICP

US92560A1060

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 07:59:14 10/05/2024 pm IST 		5-day change 1st Jan Change
0.444 USD 0.00% Intraday chart for Vicapsys Life Sciences, Inc. 0.00% -83.80%
2023 Vicapsys Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
2023 Vicapsys Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022
Capitalization 1 7.669 4.183 26.22 35.01 31.19
Enterprise Value (EV) 1 7.582 3.919 26.22 34.8 31.18
P/E ratio -11.8 x -10.9 x -34.2 x -149 x -30.9 x
Yield - - - - -
Capitalization / Revenue 1,03,26,885 x - - - -
EV / Revenue 1,02,10,629 x - - - -
EV / EBITDA -3.89 x -3.91 x -35.7 x -114 x -50.8 x
EV / FCF -67,43,356 x -34,08,262 x 1,07,94,29,283 x -10,95,46,985 x -2,71,37,32,852 x
FCF Yield -0% -0% 0% -0% -0%
Price to Book -102 x 89 x -57.4 x -325 x -32.8 x
Nbr of stocks (in thousands) 2,789 2,789 17,483 17,507 31,189
Reference price 2 2.750 1.500 1.500 2.000 1.000
Announcement Date 12/02/20 30/03/20 17/09/21 16/03/22 14/04/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales - 0.7426 - - - -
EBITDA 1 -3.055 -1.948 -1.003 -0.7344 -0.3055 -0.6133
EBIT 1 -3.234 -2.202 -1.034 -0.7658 -0.3369 -0.6446
Operating Margin - -296.55% - - - -
Earnings before Tax (EBT) 1 -3.234 -2.202 -1.034 -0.7658 -0.2369 -0.9848
Net income 1 -3.234 -2.202 -1.41 -0.7658 -0.2369 -0.9848
Net margin - -296.55% - - - -
EPS 2 -0.5356 -0.2328 -0.1377 -0.0438 -0.0134 -0.0323
Free Cash Flow - -1.124 -1.15 0.0243 -0.3176 -0.0115
FCF margin - -151.42% - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 12/02/20 12/02/20 30/03/20 17/09/21 16/03/22 14/04/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 0.55 0.09 0.26 0 0.22 0.01
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - -1.12 -1.15 0.02 -0.32 -0.01
ROE (net income / shareholders' equity) - 2,133% -4,283% 1,041% 83% 184%
ROA (Net income/ Total Assets) - -147% -86.5% -86.8% -42.2% -121%
Assets 1 - 1.499 1.63 0.882 0.5616 0.8144
Book Value Per Share 2 0.0100 -0.0300 0.0200 -0.0300 -0.0100 -0.0300
Cash Flow per Share 2 0.0900 0.0100 0.0200 0 0.0100 0
Capex 1 0 0.04 - - - -
Capex / Sales - 5.12% - - - -
Announcement Date 12/02/20 12/02/20 30/03/20 17/09/21 16/03/22 14/04/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
VICAPSYS LIFE SCIENCES, INC. Stock Vicapsys Life Sciences, Inc.
-83.80% 14.24M
MODERNA, INC. Stock Moderna, Inc.
+29.77% 49.18B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.00% 42.11B
LONZA GROUP AG Stock Lonza Group AG
+50.47% 40.37B
CELLTRION, INC. Stock Celltrion, Inc.
-5.26% 28.85B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.68% 26.09B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.99% 18.71B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+8.22% 13.26B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.41% 12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.62% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. VICP Stock
  4. Financials Vicapsys Life Sciences, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW